World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
90
Citations
35628
World Ranking
12079
National Ranking
354

Namiki Izumi publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Namiki Izumi sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 677 publications — 79th percentile

79% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Namiki Izumi D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Namiki Izumi sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 90 D-Index — 41st percentile

41% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Namiki Izumi is affiliated with Musashino Red Cross Hospital in Japan and specializes in medical research with a strong focus on hepatology. Their work spans multiple subfields including hepatology, epidemiology, oncology, cancer research, and surgery, contributing extensively to the field of medicine.

The scientist's research covers a variety of topics primarily related to liver disease and cancer. These main topics include:

  • Liver Disease Diagnosis and Treatment
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Hepatitis C Virus Research
  • Hepatitis B Virus Studies
  • Liver Disease and Transplantation
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Cancer, Lipids, and Metabolism

Namiki Izumi has contributed to numerous research articles published in prominent journals. Notable recent papers include:

  • Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update, 2021, Liver Cancer
  • Surgery versus Radiofrequency Ablation for Small Hepatocellular Carcinoma: A Randomized Controlled Trial (SURF Trial), 2021, Liver Cancer
  • Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis, 2023, The Lancet. Gastroenterology & Hepatology
  • Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma, 2022, Liver Cancer
  • Liver Stiffness on Magnetic Resonance Elastography and the MEFIB Index and Liver-Related Outcomes in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Individual Participants, 2022, Gastroenterology

Their research has appeared frequently in specific publication venues such as:

  • Hepatology Research
  • Alimentary Pharmacology & Therapeutics
  • JGH Open
  • Journal of Clinical Oncology
  • Journal of Hepatology

Namiki Izumi has collaborated extensively with several co-authors over their career. Frequent co-authors include:

  • Masayuki Kurosaki
  • Nobuharu Tamaki
  • Yutaka Yasui
  • Kaoru Tsuchiya
  • Hiroyuki Nakanishi

Best Publications

  • Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.

    Yasuhito Tanaka;Nao Nishida;Masaya Sugiyama;Masayuki Kurosaki

  • Mutations in the Nonstructural Protein 5a Gene and Response to Interferon in Patients with Chronic Hepatitis C Virus 1b Infection

    Nobuyuki Enomoto;Ikuo Sakuma;Yasuhiro Asahina;Masayuki Kurosaki

  • Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Guidelines Proposed by the Japan Society of Hepatology (JSH) 2010 Updated Version

    Masatoshi Kudo;Namiki Izumi;Norihiro Kokudo;Osamu Matsui

  • Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region.

    N Enomoto;I Sakuma;Y Asahina;M Kurosaki

  • Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection.

    Hiromitsu Kumada;Yoshiyuki Suzuki;Kenji Ikeda;Joji Toyota

  • JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan

    Masatoshi Kudo;Osamu Matsui;Namiki Izumi;Hiroko Iijima

  • Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.

    Masatoshi Kudo;Kazuomi Ueshima;Masafumi Ikeda;Takuji Torimura

  • Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial

    Maria Buti;Edward Gane;Wai Kay Seto;Henry L.Y. Chan

  • Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion

    Takashi Kokudo;Kiyoshi Hasegawa;Yutaka Matsuyama;Tadatoshi Takayama

  • Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines)

    Norihiro Kokudo;Kiyoshi Hasegawa;Masaaki Akahane;Hiroshi Igaki

  • Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial.

    Masashi Mizokami;Osamu Yokosuka;Tetsuo Takehara;Naoya Sakamoto

  • Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update.

    Norihiro Kokudo;Nobuyuki Takemura;Kiyoshi Hasegawa;Tadatoshi Takayama

  • Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update.

    Masatoshi Kudo;Yusuke Kawamura;Kiyoshi Hasegawa;Ryosuke Tateishi

  • Comparison of resection and ablation for hepatocellular carcinoma: A cohort study based on a Japanese nationwide survey

    Kiyoshi Hasegawa;Norihiro Kokudo;Masatoshi Makuuchi;Namiki Izumi

  • Branched-chain amino acids as pharmacological nutrients in chronic liver disease.

    Takumi Kawaguchi;Namiki Izumi;Michael R. Charlton;Michio Sata

  • 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection

    Kosh Agarwal;Maurizia Brunetto;Wai Kay Seto;Young-Suk Lim

  • Influence of Hepatitis B Virus Genotypes on the Intra- and Extracellular Expression of Viral DNA and Antigens

    Masaya Sugiyama;Yasuhito Tanaka;Takanobu Kato;Etsuro Orito

  • Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection

    Yasuhiro Asahina;Kaoru Tsuchiya;Nobuharu Tamaki;Itsuko Hirayama

  • Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.

    Masatoshi Kudo;Kazuomi Ueshima;Osamu Yokosuka;Sadahisa Ogasawara

  • RAPID COMMUNICATION Daclatasvir Plus Asunaprevir for Chronic HCV Genotype 1b Infection

    Hiromitsu Kumada;Yoshiyuki Suzuki;Kenji Ikeda;Joji Toyota

Frequent Co-Authors

Yutaka Yasui
Yutaka Yasui St. Jude Children's Research Hospital
Nobuyuki Enomoto
Nobuyuki Enomoto University of Yamanashi
Hiroyuki Nakanishi
Hiroyuki Nakanishi Kumamoto University
Masatoshi Kudo
Masatoshi Kudo Kindai University
Norihiro Kokudo
Norihiro Kokudo National Center For Global Health and Medicine
Michiie Sakamoto
Michiie Sakamoto Keio University
Yasuhito Tanaka
Yasuhito Tanaka Kumamoto University
Masashi Mizokami
Masashi Mizokami National Center For Global Health and Medicine
Hiromitsu Kumada
Hiromitsu Kumada Fukuoka University
Shuichi Kaneko
Shuichi Kaneko Kanazawa University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring the world of medicine doesn’t just mean attending medical school in person. Many students now start or advance their healthcare careers with flexible and affordable online degree options. These programs allow you to study on your schedule, often while keeping your current job.

For those interested in advanced practice, there are several online nurse practitioner programs that prepare registered nurses for leadership and specialized clinical roles. If you are just starting, consider earning your degree through a reputable nursing school online. These programs can help you begin your career as a nurse or move forward as a registered nurse.

Ambitious nurses may enhance their credentials and impact the healthcare field by enrolling in online phd programs in nursing, paving the way for careers in research, teaching, or upper management. Those seeking a more budget-friendly path to advance from RN to BSN can review the cheapest bsn programs online.

No matter your starting point, these online options create more accessible pathways for aspiring healthcare professionals in the USA.

Best Scientists Citing Namiki Izumi

Trending Scientists

Recently Published Articles